E. coli gain edge by changing their diets in inflammatory bowel disease
One of the most common forms of IBD, called Crohn’s disease, is characterized by inflammation within the digestive tract and can lead to severe diarrhea, pain and weight loss. What causes IBD is still a mystery, but scientists now know that the gut microbiome, composed of the trillions of bacteria that make their home inside the intestines, are key players.
In a new paper in Nature Microbiology, Michigan Medicine researchers describe how bad bacteria gain a foothold over good bacteria in IBD and how something as simple as a diet change might reverse it. “The same bacteria are present in healthy and inflamed digestive tracts,” says Nobuhiko Kamada, Ph.D., of the division of gastroenterology in the department of internal medicine. “They just change their competition. We wondered what is the mechanism behind this?”
Although E. coli, the notorious bacteria behind many cases of food poisoning, is present in a normal healthy gut, the disease-causing form of the bacteria is able to outcompete its more benign cousins when the gut is inflamed. In earlier work within the Michigan Microbiome Project , Kamada’s team showed that the bad version of E. coli is usually held in check by good E. coli and other beneficial bacterial species through the metabolism of carbohydrates, the preferred source of nutrients for E. coli. Under inflammation however, the amount of good bacterial species is reduced, leaving less available sugar for E. coli to use and grow. Yet, the disease-causing E. coli are still able to take over.
The team hypothesized that the bad E. coli must change their dietary preference from sugar to something else, giving it an edge over other bacteria. In fact, their experiments with mouse models found that the bad E. coli developed a taste for amino acids, particularly serine, when their environment was inflamed. “We found that pathogenic E. coli had upregulated genes for serine metabolism,” said first author Sho Kitamoto, Ph.D., a research fellow in Kamada’s lab. Furthermore, the team was able to control the overgrowth by feeding mice with IBD a low serine diet.
Together, these findings hint at a possible mechanism for controlling bad bacteria through nutrition. “Of course, we could use antibiotics to kill the bad bacteria,” says Kamada. “But the gut microbiota plays a beneficial role to the hosts biology, and antibiotics kill the good guys along with the bad guys.”
They hope to eventually collaborate with clinicians to investigate the effects of personalized therapeutic diets for patients with IBD. Says Kamada, “We have to carefully consider a patient’s disease status. One type of diet might be effective in patients under remission but not in patients with active disease.”